ALLMedicine™ Attention Deficit Hyperactivity Disorder Center
Research & Reviews 6,761 results
https://doi.org/10.1080/09297049.2021.1917529
Child Neuropsychology : a Journal on Normal and abNormal ... Peterson RK, Jones K et. al.
Apr 19th, 2021 - Sluggish Cognitive Tempo (SCT) describes a pattern of under-activity, poor initiation, and slowness. It was first reported within the Attention Deficit Hyperactivity Disorder (ADHD) literature and found to be positively associated with the inatten...
https://doi.org/10.1017/S1092852921000328
CNS Spectrums; Naguy A, El-Sheshaie A et. al.
Apr 19th, 2021 - Solriamfetol for attention deficit hyperactivity disorder.|2021|Naguy A,El-Sheshaie A,Elsori DH,Alamiri B,|
https://doi.org/10.1080/02643294.2021.1908979
Cognitive Neuropsychology; Grandjean A, Suarez I et. al.
Apr 12th, 2021 - The deficit in "interference control" found in children with Attention Deficit Hyperactivity Disorder (ADHD) could be due to two distinct processes, which are not disentangled in most studies: a larger susceptibility to activating prepotent respon...
https://doi.org/10.1007/s10578-021-01155-0 10.1097/00004583-199907000-00011 10.1542/peds.2008-1770 10.1016/j.neuropsychologia.2015.09.032 10.1136/adc.2005.088054 10.1093/pch/11.8.507 10.3389/fped.2019.00474 10.1016/j.ridd.2011.01.017 10.1249/MSS.0000000000001940 10.1155/2017/2760716 10.1111/j.1469-8749.2009.03520.x 10.1177/000841749806500203 10.1016/j.humov.2013.10.003 10.1016/j.ridd.2011.01.040 10.1016/j.humov.2016.03.004 10.1016/j.jsams.2017.05.007 10.1007/s40279-015-0351-6 10.1111/dmcn.14237 10.1177/0883073809333537 10.1212/WNL.50.4.1087 10.1001/jama.288.14.1740 10.1177/088307389801300904 10.1016/j.humov.2005.10.006 10.1375/twin.12.4.381 10.1016/j.ridd.2014.09.023 10.1097/00004583-200006000-00014 10.1097/00004583-199309000-00024 10.2105/AJPH.2015.302630 10.1016/j.ridd.2013.07.021 10.1111/pcn.12096 10.1001/archpsyc.1983.04390010091012 10.1111/j.1440-1819.2007.01634.x 10.1016/j.ridd.2017.08.003 10.1017/S0012162299000341 10.1111/j.1469-8749.2003.tb00952.x 10.1016/j.ridd.2011.02.009 10.1016/j.ypmed.2006.10.004 10.1139/apnm-2016-0151 10.1186/s12889-015-2582-8 10.1136/bmjopen-2019-029784 10.1249/MSS.0000000000001590 10.1111/j.1469-8749.2011.04171.x 10.1111/j.1469-7610.1989.tb00236.x 10.1080/02640410802334196 10.1123/apaq.21.3.197 10.1007/s00787-019-01311-x 10.1016/S0003-9993(97)90138-6 10.1016/j.pnpbp.2010.01.013 10.1016/j.pscychresns.2015.08.001 10.1007/s00221-015-4243-7 10.1080/87565641.2018.1466888 10.1123/pes.24.3.435 10.1080/02701367.2009.10599592 10.1001/archpedi.159.1.46 10.1542/peds.2006-2697 10.1177/108705470000400302 10.1007/s40474-014-0012-8
Child Psychiatry and Human Development; James ME, King-Dowling S et. al.
Apr 10th, 2021 - Developmental coordination disorder (DCD) is often comorbid with attention-deficit/hyperactivity disorder (ADHD). While children with DCD engage in less moderate-to-vigorous physical activity (MVPA) compared to typically developing (TD) children, ...
https://doi.org/10.1177/0897190021999781
Journal of Pharmacy Practice; Pagliaro A, Mattio B et. al.
Apr 5th, 2021 - In this report, we discuss the case of a 9-year-old male with Attention Deficit Hyperactivity Disorder (ADHD) on long-term methylphenidate and guanfacine who experienced acute orofacial dystonia that resolved immediately with the administration of...
Guidelines 15 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888126/
Annals of General Psychiatry; Sukmajaya AC
Feb 15th, 2021 - Gut–brain axis (GBA) is a system widely studied nowadays, especially in the neuropsychiatry field. It is postulated to correlate with many psychiatric conditions, one of them being attention-deficit hyperactivity disorder (ADHD). ADHD is a disorde...
https://bpded.biomedcentral.com/articles/10.1186/s40479-021-00144-y
Borderline Personality Disorder and Emotion Dysregulation; Moukhtarian TR
Feb 11th, 2021 - Emotional dysregulation (ED) is a core diagnostic symptom in borderline personality disorder (BPD) and an associated feature of attention-deficit/hyperactivity disorder (ADHD). We aimed to investigate differences in dynamical indices of ED in dail...
https://pubmed.ncbi.nlm.nih.gov/33127072/
Journal of Psychiatric Research; Stefano P
Oct 23rd, 2020 - In the broader list of cognitive concerns, neuropsychological testing has shown that attentional impairment may have a specific burden in Fibromyalgia Syndrome (FMS).
https://www.nccih.nih.gov/health/providers/digest/adhd-and-complementary-health-approaches-science
NCCIH Clinical Digest;
Mar 30th, 2019 - ADHD and Complementary Health Approaches
https://www.empr.com/home/news/adhansia-xr-approved-for-the-treatment-of-pediatric-adult-adhd/
Feb 28th, 2019 - The Food and Drug Administration (FDA) has approved Adhansia XR (methylphenidate HCl extended-release; Adlon Therapeutics), a central nervous system stimulant, for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 year...
Drugs 433 results see all →
Clinicaltrials.gov 7,403 results
https://doi.org/10.1080/09297049.2021.1917529
Child Neuropsychology : a Journal on Normal and abNormal ... Peterson RK, Jones K et. al.
Apr 19th, 2021 - Sluggish Cognitive Tempo (SCT) describes a pattern of under-activity, poor initiation, and slowness. It was first reported within the Attention Deficit Hyperactivity Disorder (ADHD) literature and found to be positively associated with the inatten...
https://doi.org/10.1017/S1092852921000328
CNS Spectrums; Naguy A, El-Sheshaie A et. al.
Apr 19th, 2021 - Solriamfetol for attention deficit hyperactivity disorder.|2021|Naguy A,El-Sheshaie A,Elsori DH,Alamiri B,|
https://doi.org/10.1080/02643294.2021.1908979
Cognitive Neuropsychology; Grandjean A, Suarez I et. al.
Apr 12th, 2021 - The deficit in "interference control" found in children with Attention Deficit Hyperactivity Disorder (ADHD) could be due to two distinct processes, which are not disentangled in most studies: a larger susceptibility to activating prepotent respon...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a
Apr 11th, 2021 - Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Qelbree is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention Deficit Hyperac...
https://doi.org/10.1007/s10578-021-01155-0 10.1097/00004583-199907000-00011 10.1542/peds.2008-1770 10.1016/j.neuropsychologia.2015.09.032 10.1136/adc.2005.088054 10.1093/pch/11.8.507 10.3389/fped.2019.00474 10.1016/j.ridd.2011.01.017 10.1249/MSS.0000000000001940 10.1155/2017/2760716 10.1111/j.1469-8749.2009.03520.x 10.1177/000841749806500203 10.1016/j.humov.2013.10.003 10.1016/j.ridd.2011.01.040 10.1016/j.humov.2016.03.004 10.1016/j.jsams.2017.05.007 10.1007/s40279-015-0351-6 10.1111/dmcn.14237 10.1177/0883073809333537 10.1212/WNL.50.4.1087 10.1001/jama.288.14.1740 10.1177/088307389801300904 10.1016/j.humov.2005.10.006 10.1375/twin.12.4.381 10.1016/j.ridd.2014.09.023 10.1097/00004583-200006000-00014 10.1097/00004583-199309000-00024 10.2105/AJPH.2015.302630 10.1016/j.ridd.2013.07.021 10.1111/pcn.12096 10.1001/archpsyc.1983.04390010091012 10.1111/j.1440-1819.2007.01634.x 10.1016/j.ridd.2017.08.003 10.1017/S0012162299000341 10.1111/j.1469-8749.2003.tb00952.x 10.1016/j.ridd.2011.02.009 10.1016/j.ypmed.2006.10.004 10.1139/apnm-2016-0151 10.1186/s12889-015-2582-8 10.1136/bmjopen-2019-029784 10.1249/MSS.0000000000001590 10.1111/j.1469-8749.2011.04171.x 10.1111/j.1469-7610.1989.tb00236.x 10.1080/02640410802334196 10.1123/apaq.21.3.197 10.1007/s00787-019-01311-x 10.1016/S0003-9993(97)90138-6 10.1016/j.pnpbp.2010.01.013 10.1016/j.pscychresns.2015.08.001 10.1007/s00221-015-4243-7 10.1080/87565641.2018.1466888 10.1123/pes.24.3.435 10.1080/02701367.2009.10599592 10.1001/archpedi.159.1.46 10.1542/peds.2006-2697 10.1177/108705470000400302 10.1007/s40474-014-0012-8
Child Psychiatry and Human Development; James ME, King-Dowling S et. al.
Apr 10th, 2021 - Developmental coordination disorder (DCD) is often comorbid with attention-deficit/hyperactivity disorder (ADHD). While children with DCD engage in less moderate-to-vigorous physical activity (MVPA) compared to typically developing (TD) children, ...
News 221 results
https://www.medscape.com/viewarticle/948727
Apr 4th, 2021 - The US Food and Drug Administration (FDA) has approved the nonstimulant medication viloxazine extended-release capsules (Qelbree, Supernus Pharmaceuticals) for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 to ...
https://www.medscape.com/viewarticle/947075
Mar 7th, 2021 - The US Food and Drug Administration (FDA) has approved a new, once-daily oral stimulant medication for treatment of attention deficit hyperactivity disorder (ADHD) in people aged 6 years and older. Azstarys (KemPharm, Inc) combines extended-releas...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888126/
Annals of General Psychiatry; Sukmajaya AC
Feb 15th, 2021 - Gut–brain axis (GBA) is a system widely studied nowadays, especially in the neuropsychiatry field. It is postulated to correlate with many psychiatric conditions, one of them being attention-deficit hyperactivity disorder (ADHD). ADHD is a disorde...
https://www.medscape.com/viewarticle/945720
Feb 11th, 2021 - Exposure to Group A streptococcus (GAS) does not appear to worsen symptoms of Tourette syndrome and other chronic tic disorders (CTDs) in children and adolescents, new research suggests. Investigators studied over 700 children and teenagers with C...
https://bpded.biomedcentral.com/articles/10.1186/s40479-021-00144-y
Borderline Personality Disorder and Emotion Dysregulation; Moukhtarian TR
Feb 11th, 2021 - Emotional dysregulation (ED) is a core diagnostic symptom in borderline personality disorder (BPD) and an associated feature of attention-deficit/hyperactivity disorder (ADHD). We aimed to investigate differences in dynamical indices of ED in dail...
